Edit Module

Pfizer Animal Health Acquires Synbiotics



Published:

Juan Ramon Alaix, president of Pfizer Animal Health, which has acquired Synbiotics Corp.

Pfizer Animal Health of New York has acquired Synbiotics Corp., a Kansas City, Mo.-based developer and manufacturer of immunodiagnostic tests for companion and food production animals.


The acquisition marks Pfizer Animal Health’s entry into the veterinary diagnostics sector.

“By integrating animal health diagnostics with our innovative portfolio of vaccines and medicines, we can do more to help veterinarians deliver optimal care for livestock and companion animals and provide the right medicine to the right animal at the right time,” said Juan Ramon Alaix, president of Pfizer Animal Health.

The move will also allow the company to expand into products for diagnostic reference laboratories and reproductive services for canine breeders, Alaix added.

Synbiotics estimates that its common shareholders will be entitled to receive up to about $0.306 per share in cash in connection with acquisition, of which about $0.019 per share will be held in escrow as a fund against which Pfizer may make claims for losses arising from any breaches of Synbiotics’ representations, warranties, covenants and agreements and similar customary matters, according to Paul Hays, CEO of Synbiotics.

Veterinary immunodiagnostics, a methodology using antigen-antibody reaction to detect viruses or bacteria in animals, is a sector growing an estimated 8 percent annually, twice the rate of the animal health industry as a whole, according to Pfizer Animal Health. The global immunodiagnostics market is valued at $735 million, the company noted citing industry sources.

The growth is attributed to increased interest among companion animal owners in monitoring the health and maintaining wellness of their pets and livestock producers placing greater emphasis on immunodiagnostics to safeguard the health of livestock animals.

<Home>

Edit Module
Edit ModuleShow Tags

Archive »Read More

Zoetis launches Clavamox Chewable for dogs, cats

Zoetis announced the commercial launch of Clavamox Chewable (amoxicillin and clavulanate potassium tablets), which is effective in treating skin infections in dogs and cats, periodontal infections in dogs, and urinary tract infections in cats, according to the company.

​2017 National Veterinary Scholars Symposium exposes students to biomedical research

Approximately 650 veterinary students and researchers from 38 veterinary schools from the U.S., Canada, the Caribbean, the Netherlands, and France gathered Aug. 3-6 at the National Institutes of Health (NIH) to discuss innovative animal health research and the future of veterinary medicine.

Four reasons veterinary clients avoid regular checkups for their cats—and what you can do about it

A recent survey found 92 percent of cat owners say their cat’s health is important to them, but only half of all American cats taken to the veterinarian by their caretakers on a regular basis; inspire cat owners to participate in Take Your Cat to Vet Day on August 22.

Add your comment:
Edit Module
Edit Module
Edit ModuleEdit ModuleShow Tags Edit Module
Edit Module Edit Module
Edit ModuleShow Tags

Events


Show More...
Edit Module
Edit Module